Development and evaluation of a preliminary risk assessment model for psychological distress among patients with brain tumors: a cross-sectional analysis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Development and evaluation of a preliminary risk assessment model for psychological distress among patients with brain tumors: a cross-sectional analysis

  • By

  • Ying Li

  • Yuyu Duan

  • Yangmei Su

  • Zhiman Zheng

  • Dongqi Zou

  • Zhihuan Zhou

  • January 22, 2026

Share

  • 1

    Brain tumors significantly impact patients' quality of life, with 44.5% to 76.0% experiencing clinically significant psychological distress.

  • 2

    Financial toxicity correlates strongly with psychological distress in brain tumor patients, exacerbating anxiety and depression.

  • 3

    Self-efficacy is inversely related to psychological distress, with higher self-efficacy linked to better coping and quality of life.

  • 4

    Adaptive coping strategies, such as seeking social support, can mitigate psychological distress in brain tumor patients.

  • 5

    The study developed a predictive model for psychological distress, focusing on financial toxicity, self-efficacy, and coping strategies.

Original Source(s)

Development and evaluation of a preliminary risk assessment model for psychological distress among patients with brain tumors: a cross-sectional analysis

  • by Ying Li, Yuyu Duan, Yangmei Su, Zhiman Zheng, Dongqi Zou, Zhihuan Zhou

  • January 22, 2026

Related Content

Upfront stereotactic radiosurgery for large posterior fossa metastases: a multicenter evaluation of clinical outcomes

Fellowship-Trained Neuro-Oncologist Nishika Karbhari, M.D., Joins Baptist Health Herbert Wertheim Cancer Institute

Fellowship-trained neuro-oncologist Nishika Karbhari, M.D., has joined Baptist Health Herbert Wertheim Cancer Institute.

  • by

  • September 3, 2026

  • 2 min
FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.